SCA
GSK icon

Snowden Capital Advisors’s GSK GSK Stock Holding History

Snowden Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Buy
7,049
+365
+5% +$19.3K 0.01% 974
2026
Q1 		$374K Sell
6,684
-4,053
-38% -$220K 0.01% 929
2025
Q4 		$531K Sell
10,737
-963
-8% -$44.9K 0.01% 776
2025
Q3 		$510K Buy
11,700
+236
+2% +$9.22K 0.01% 768
2025
Q2 		$445K Buy
11,464
+5,895
+106% +$225K 0.01% 818
2025
Q1 		$218K Sell
5,569
-1,461
-21% -$53.5K 0.01% 1125
2024
Q4 		$247K Sell
7,030
-20,341
-74% -$732K 0.01% 1077
2024
Q3 		$1.13M Buy
27,371
+2,429
+10% +$99.4K 0.03% 484
2024
Q2 		$971K Sell
24,942
-4,081
-14% -$172K 0.03% 513
2024
Q1 		$1.26M Buy
29,023
+4,472
+18% +$184K 0.04% 442
2023
Q4 		$910K Sell
24,551
-2,691
-10% -$96.6K 0.03% 469
2023
Q3 		$988K Sell
27,242
-1,194
-4% -$42.4K 0.04% 423
2023
Q2 		$1.01M Buy
28,436
+5,146
+22% +$185K 0.04% 456
2023
Q1 		$829K Buy
23,290
+779
+3% +$27.3K 0.03% 512
2022
Q4 		$791K Buy
22,511
+2,444
+12% +$81.4K 0.03% 512
2022
Q3 		$590K Sell
20,067
-7,693
-28% -$292K 0.03% 586
2022
Q2 		$1.51M Buy
27,760
+14,494
+109% +$800K 0.07% 316
2022
Q1 		$722K Buy
13,266
+11,493
+648% +$624K 0.03% 522
2021
Q4 		$97K Buy
+1,773
New +$92.2K 0.01% 848
2021
Q1 		– Sell
-42,274
Closed -$1.94M – 803
2020
Q4 		$1.94M Buy
42,274
+2,256
+6% +$104K 0.13% 216
2020
Q3 		$1.88M Buy
40,018
+2,426
+6% +$122K 0.15% 190
2020
Q2 		$1.92M Buy
37,592
+2,049
+6% +$105K 0.16% 185
2020
Q1 		$1.68M Buy
35,543
+3,098
+10% +$165K 0.18% 170
2019
Q4 		$1.91M Buy
32,445
+675
+2% +$37.5K 0.17% 181
2019
Q3 		$1.69M Buy
31,770
+1,096
+4% +$56.4K 0.17% 180
2019
Q2 		$1.53M Buy
30,674
+3,371
+12% +$169K 0.16% 197
2019
Q1 		$1.43M Buy
+27,303
New +$1.36M 0.16% 201

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Snowden Capital Advisors's GSK Position: Q2 2026 in Review

Snowden Capital Advisors increased its GSK (GSK) stake by 5.5% in Q2 2026, buying an estimated $19.3K and bringing the position to 7,049 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #974.

Snowden Capital Advisors first reported a position in GSK in Q1 2019 and has held it in 27 quarters since. The position peaked at $1.94M in Q4 2020. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Snowden Capital Advisors held 7,049 shares of GSK worth $372K as of Q2 2026.
  • Snowden Capital Advisors bought 365 GSK shares in Q2 2026, an estimated $19.3K.
  • GSK made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #974 holding.
  • Snowden Capital Advisors first reported a position in GSK in Q1 2019 and has held it in 27 quarters since.
  • Snowden Capital Advisors's GSK position peaked at $1.94M in Q4 2020.
  • 1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.